<p>木星资产管理有限公司在最近向美国证券交易委员会提交的文件中表示，在第二季度将其在 Aurinia Pharmaceuticals Inc（NASDAQ:AUPH - 免费报告）TSE: AUP 的股份增加了 24.1%。该基金在季度内购买了额外的 181,093 股后，持有 933,862 股该生物技术公司的股票。木星资产管理有限公司在最近一个季度末持有 Aurinia Pharmaceuticals 的 0.71% 股份，价值 791 万美元。</p>
<ul>
<li>这两只医疗保健股票在 2023 年翻了一番</li>
</ul>
<p>其他对冲基金和机构投资者最近也买卖了该公司的股票。MAI 资本管理在第一季度购买了价值 39,000 美元的 Aurinia Pharmaceuticals 新头寸。Xponance Inc.在第一季度购买了价值约 82,000 美元的 Aurinia Pharmaceuticals 新头寸。Kazazian 资产管理公司在第一季度购买了价值约 84,000 美元的 Aurinia Pharmaceuticals 新头寸。麦肯齐金融公司在第一季度购买了价值约 86,000 美元的 Aurinia Pharmaceuticals 新股份。最后，先锋个性化指数管理公司在第二季度购买了价值约 92,000 美元的 Aurinia Pharmaceuticals 新股份。对冲基金和其他机构投资者持有该公司 36.83% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些研究分析师最近对 AUPH 股票发表了评论。HC Wainwright 在 7 月 30 日的研究报告中重申了对 Aurinia Pharmaceuticals 的 “买入” 评级，并设定了 17.00 美元的目标价。Bloom Burton 在 11 月 5 日的研究报告中将 Aurinia Pharmaceuticals 的评级从 “适度买入” 下调至 “持有”。Jefferies 金融集团在 11 月 7 日的研究报告中将 Aurinia Pharmaceuticals 的评级从 “持有” 上调至 “买入”，并将其目标价从 10.00 美元提高至 21.00 美元。加拿大皇家银行在 11 月 5 日的研究报告中重申了 “行业表现” 评级，并将 Aurinia Pharmaceuticals 的目标价设定为 15.00 美元（从 9.00 美元上调）。最后，Weiss 评级在 10 月 8 日的报告中重申了对 Aurinia Pharmaceuticals 的 “持有（c）” 评级。两位股票研究分析师对该股票给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 17.67 美元。</p>
<p><strong>查看我们最新的 Aurinia Pharmaceuticals 股票报告</strong></p>
<h2>Aurinia Pharmaceuticals 股票表现</h2>
<p>AUPH 在周五开盘价为 15.22 美元。该公司的流动比率为 5.23，速动比率为 4.63，债务与股本比率为 0.18。Aurinia Pharmaceuticals Inc 的 12 个月低点为 6.55 美元，12 个月高点为 16.20 美元。该公司的 50 日移动平均线为 12.54 美元，200 日移动平均线为 10.37 美元。该公司的市值为 20.1 亿美元，市盈率为 35.40，贝塔值为 1.30。</p>
<p>Aurinia Pharmaceuticals（NASDAQ:AUPH - 获取免费报告）TSE: AUP 最近在 11 月 4 日发布了季度财报。该生物技术公司报告季度每股收益为 0.23 美元，超出共识预期的 0.16 美元，超出 0.07 美元。该季度的营业收入为 7347 万美元，而共识预期为 6770 万美元。Aurinia Pharmaceuticals 的净利润率为 23.31%，股本回报率为 20.06%。Aurinia Pharmaceuticals 已设定 2025 财年的每股收益指导。分析师平均预计 Aurinia Pharmaceuticals Inc 在本年度将发布 0.11 美元的每股收益。</p>
<h2>Aurinia Pharmaceuticals 简介</h2>
<p>（免费报告）</p>
<p>Aurinia Pharmaceuticals Inc 是一家商业阶段的生物制药公司，专注于开发和商业化治疗美国各种未满足医疗需求的疾病的疗法。它提供 LUPKYNIS 用于治疗活跃狼疮性肾炎的成年患者。它与大冢制药株式会社签订了合作和许可协议。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Aurinia Pharmaceuticals</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>尽管第三季度业绩出色，dLocal 仍下跌——投资者错过了什么</li>
<li>初学者如何阅读股票图表</li>
<li>Ondas Holdings 在无人机需求激增中发出反弹信号</li>
<li>股息支付比率计算器</li>
<li>在艾格的魔法触碰下，迪士尼 2026 年的前景变得更加光明</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVQSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVQSA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aurinia Pharmaceuticals 吗？</h2>
<p>在考虑 Aurinia Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Aurinia Pharmaceuticals 并不在名单上。</p>
<p>虽然 Aurinia Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Aurinia制药

<p>Jupiter Asset Management Ltd. 在第二季度将其在 Aurinia Pharmaceuticals 的股份增加了 24.1%，目前持有 933,862 股，价值 791 万美元。分析师对 AUPH 的评级褒贬不一，普遍认为应 “持有”，目标价为 17.67 美元。该股票开盘价为 15.22 美元，市值为 20.1 亿美元。Aurinia 报告第三季度每股收益为 0.23 美元，超出预期，收入为 7347 万美元。该公司专注于满足医疗需求的治疗，提供用于狼疮性肾炎的 LUPKYNIS</p>

<p>Jupiter Asset Management Ltd. increased its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 24.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 933,862 shares of the biotechnology company's stock after purchasing an additional 181,093 shares during the quarter. Jupiter Asset Management Ltd. owned 0.71% of Aurinia Pharmaceuticals worth $7,910,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>木星资产管理有限公司在最近向美国证券交易委员会提交的文件中表示，在第二季度将其在 Aurinia Pharmaceuticals Inc（NASDAQ:AUPH - 免费报告）TSE: AUP 的股份增加了 24.1%。该基金在季度内购买了额外的 181,093 股后，持有 933,862 股该生物技术公司的股票。木星资产管理有限公司在最近一个季度末持有 Aurinia Pharmaceuticals 的 0.71% 股份，价值 791 万美元。</p>
</div><ul>
<li>These 2 Healthcare Stocks Have Doubled in 2023</li>
</ul>
<div class="lb-trans"><ul>
<li>这两只医疗保健股票在 2023 年翻了一番</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently bought and sold shares of the company. MAI Capital Management bought a new position in Aurinia Pharmaceuticals during the first quarter valued at $39,000. Xponance Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the 1st quarter worth about $82,000. Kazazian Asset Management LLC bought a new position in Aurinia Pharmaceuticals during the 1st quarter valued at about $84,000. Mackenzie Financial Corp purchased a new stake in Aurinia Pharmaceuticals in the 1st quarter worth about $86,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in Aurinia Pharmaceuticals in the 2nd quarter worth about $92,000. Hedge funds and other institutional investors own 36.83% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也买卖了该公司的股票。MAI 资本管理在第一季度购买了价值 39,000 美元的 Aurinia Pharmaceuticals 新头寸。Xponance Inc.在第一季度购买了价值约 82,000 美元的 Aurinia Pharmaceuticals 新头寸。Kazazian 资产管理公司在第一季度购买了价值约 84,000 美元的 Aurinia Pharmaceuticals 新头寸。麦肯齐金融公司在第一季度购买了价值约 86,000 美元的 Aurinia Pharmaceuticals 新股份。最后，先锋个性化指数管理公司在第二季度购买了价值约 92,000 美元的 Aurinia Pharmaceuticals 新股份。对冲基金和其他机构投资者持有该公司 36.83% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research analysts have recently commented on AUPH shares. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Bloom Burton downgraded Aurinia Pharmaceuticals from a &#34;moderate buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, November 5th. Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating and increased their target price for the stock from $10.00 to $21.00 in a research note on Friday, November 7th. Royal Bank Of Canada reissued a &#34;sector perform&#34; rating and set a $15.00 target price (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a &#34;hold (c)&#34; rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $17.67.</p>
<div class="lb-trans"><p>一些研究分析师最近对 AUPH 股票发表了评论。HC Wainwright 在 7 月 30 日的研究报告中重申了对 Aurinia Pharmaceuticals 的 “买入” 评级，并设定了 17.00 美元的目标价。Bloom Burton 在 11 月 5 日的研究报告中将 Aurinia Pharmaceuticals 的评级从 “适度买入” 下调至 “持有”。Jefferies 金融集团在 11 月 7 日的研究报告中将 Aurinia Pharmaceuticals 的评级从 “持有” 上调至 “买入”，并将其目标价从 10.00 美元提高至 21.00 美元。加拿大皇家银行在 11 月 5 日的研究报告中重申了 “行业表现” 评级，并将 Aurinia Pharmaceuticals 的目标价设定为 15.00 美元（从 9.00 美元上调）。最后，Weiss 评级在 10 月 8 日的报告中重申了对 Aurinia Pharmaceuticals 的 “持有（c）” 评级。两位股票研究分析师对该股票给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 17.67 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Aurinia Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Aurinia Pharmaceuticals 股票报告</strong></p>
</div><h2>Aurinia Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Aurinia Pharmaceuticals 股票表现</h2>
</div><p>AUPH opened at $15.22 on Friday. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a 12-month low of $6.55 and a 12-month high of $16.20. The firm has a 50 day moving average of $12.54 and a two-hundred day moving average of $10.37. The firm has a market capitalization of $2.01 billion, a PE ratio of 35.40 and a beta of 1.30.</p>
<div class="lb-trans"><p>AUPH 在周五开盘价为 15.22 美元。该公司的流动比率为 5.23，速动比率为 4.63，债务与股本比率为 0.18。Aurinia Pharmaceuticals Inc 的 12 个月低点为 6.55 美元，12 个月高点为 16.20 美元。该公司的 50 日移动平均线为 12.54 美元，200 日移动平均线为 10.37 美元。该公司的市值为 20.1 亿美元，市盈率为 35.40，贝塔值为 1.30。</p>
</div><p>Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.16 by $0.07. The business had revenue of $73.47 million for the quarter, compared to the consensus estimate of $67.70 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.</p>
<div class="lb-trans"><p>Aurinia Pharmaceuticals（NASDAQ:AUPH - 获取免费报告）TSE: AUP 最近在 11 月 4 日发布了季度财报。该生物技术公司报告季度每股收益为 0.23 美元，超出共识预期的 0.16 美元，超出 0.07 美元。该季度的营业收入为 7347 万美元，而共识预期为 6770 万美元。Aurinia Pharmaceuticals 的净利润率为 23.31%，股本回报率为 20.06%。Aurinia Pharmaceuticals 已设定 2025 财年的每股收益指导。分析师平均预计 Aurinia Pharmaceuticals Inc 在本年度将发布 0.11 美元的每股收益。</p>
</div><h2>Aurinia Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Aurinia Pharmaceuticals 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.</p>
<div class="lb-trans"><p>Aurinia Pharmaceuticals Inc 是一家商业阶段的生物制药公司，专注于开发和商业化治疗美国各种未满足医疗需求的疾病的疗法。它提供 LUPKYNIS 用于治疗活跃狼疮性肾炎的成年患者。它与大冢制药株式会社签订了合作和许可协议。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Aurinia Pharmaceuticals</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Ondas Holdings Signals a Rebound as Drone Demand Soars</li>
<li>Dividend Payout Ratio Calculator</li>
<li>Disney’s 2026 Outlook Brightens Under Iger's Magic Touch</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Aurinia Pharmaceuticals</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>尽管第三季度业绩出色，dLocal 仍下跌——投资者错过了什么</li>
<li>初学者如何阅读股票图表</li>
<li>Ondas Holdings 在无人机需求激增中发出反弹信号</li>
<li>股息支付比率计算器</li>
<li>在艾格的魔法触碰下，迪士尼 2026 年的前景变得更加光明</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVQSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AUPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aurinia Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aurinia Pharmaceuticals 吗？</h2>
</div><p>Before you consider Aurinia Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aurinia Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Aurinia Pharmaceuticals 并不在名单上。</p>
</div><p>While Aurinia Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aurinia Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Jupiter Asset Management Ltd. 购买了 181,093 股 Aurinia 制药公司 $AUPH 的股票